Walden Group Healthcare M&A Blog

  • Celgene Acquires Juno Therapeutics for $9b

    07/18/2018
    Celgene Corp., a $12.5b developer of therapies for cancer and inflammatory diseases is buying Juno Therapeutics Inc., a Seattle-based biotech company making cutting-edge cancer immunotherapy treatments. The Deal expands Celgene’s portfolio of blood-cancer drugs. Juno is one of leaders in a new kind of cancer treatment, known as CAR-T, that...
    Read More
  • The Impact of Trump’s Tariffs

    08/07/2018
    President Trump’s tariffs on Chinese imports could cost American medical device makers more than $1.5b annually, according to some estimates. MRIs, CT scanners, pacemakers, sonograms and other imaging components were all included in the list of items subject to the 25% tariffs that went into effect on June 6. Also included are a variety of...
    Read More
  • Sweeping New EU Regulations, Taking Effect in 2020, Will Create Upheavals in The European Medtech and IVD Markets

    07/11/2018
    Starting in 2020 medtech firms will be competing in a significantly more complicated European market. New Medical Devices Regulations (MDR) were written to strengthen device safety standards but they will make it far more onerous and expensive for medtech firms to market their products in Europe.  Because of the MDR, many smaller companies may...
    Read More
  • As part of J&J's de-diversifying, it is selling its Advanced Sterilization Products (ASP) business to Fortive Corportion (a Danaher spinout)

    06/14/2018
    Fortive Corporation, a $6.86b diversified conglomerate spinout from Danaher,  is acquiring Johnson & Johnson's Advanced Sterilization Products (ASP) business for $2.8b. ASP provides sterilization and disinfection systems and low-temperature hydrogen peroxide sterilization technology. ASP’s products include the STERRAD system for...
    Read More
  • Boston Scientific Announces Acquisition Of nVision Medical Corporation

    04/17/2018
    Boston Scientific Corporation, a $8.83b manufacturer of medical devices for cardiovascular, digestive, pulmonary and other interventional specialties is acquiring nVision Medical, a developer of a device for collecting cells from the fallopian tubes to detect ovarian cancer. Ovarian cancer is the fifth leading cause of cancer death among women....
    Read More
  • Page 1 of 812345...Last »